JC Telemedicine discusses Telemedicine Solutions & Opportunities

1
Interview Sanguina its Tech Innovations
Sanguina is at the forefront of developing tools
through accessible science and technology,
emphasizing anemia screening. The company has
launched AnemoCheck Mobile, the first-ever mobile
app designed for instant, non-invasive hemoglobin
estimation. We spoke with Sanguina CTO Robert
Mannino, who has directly experienced the impact
of medical technology, making people more easily
informed and proactive about health.
INTERVIEW
JC Telemedicine
discusses
Telemedicine
Solutions
Opportunities
Jeff Carroll
Founder at JC Telemedicine
1) What factor motivated and formed
Sanguina? Ive been chronically anemic my entire
life to the point that I need blood transfusions
every month due to beta-thalassemia. While
working on my doctorate at the Georgia Institute
of Technology under the direction of Wilbur Lam,
MD, Ph.D., now Chief Medical Officer Co-Founder
of Sanguina, I met Erika Tyburski, Sanguinas CEO
Co-Founder. She has also dealt with anemia her
whole life and, just like me, felt the need to
help others be able to track their hemoglobin
levels with an at-home screening solution. Thats
when I started creating AnemoCheck Mobile and
joined Sanguina as their Chief Technology
Officer. AnemoCheck Mobile is the first
smartphone app for completely non-invasive and
instant hemoglobin estimation, provided through a
fingernail selfie.
2
2) What is the prevalence of anemia in the United
States?
According to the Cleveland Clinic, about 3
million people in the United States have
anemia. Anemia impacts over 1.6 billion people
(25 of the worlds population) annually, with
women, pregnant women, seniors,
vegetarians/vegans, and athletes being some of
the most vulnerable groups. It can co-exist with
many conditions like cancer, HIV/AIDS, rheumatoid
arthritis, kidney disease, Crohns disease, and
more.
3) Your upcoming work AnemoCheck Home is
currently under FDA could you elaborate on the
new service? AnemoCheck Home is the only
over-the-counter product for anemia screening.
All you need is a small drop of blood, and you
will have your hemoglobin estimate in two
minutes. This product is set to release in early
2023. To watch a video on the product, click here.
4) Since the launch of the AnemoCheck Mobile app,
how is the response, and what has been your
experience so far? The AnemoCheck Mobile app was
relaunched in December of 2021, and it just hit
100,000 users, most of which take an average of 3
tests per week. We will be launching a premium
subscription soon.
5) Which new features are expected to be there in
the new update of AnemoCheck Mobile? We are
launching a premium subscription soon. Some of
the main features include MyMobile, a
personalized algorithm that will increase
accuracy by 50. One can also have unlimited
access to tests and data insights like how
hemoglobin levels have changed over time.
Consumers can sign up for a free 30-day trial
after launch.
6) Does Sanguina plan to explore and offer
solutions to various health conditions? Where do
you see yourself over the coming years? Yes,
hemoglobin is only our first target, and we plan
to expand to other health conditions. Our goal is
to get to a place where we can offer a product
suite that improves access to health monitoring.
7) In the coming years, how does Sanguina plans
to expand to other geographic
3
locations? Which other markets do you plan to
offer your solutions to? We want to offer the app
to people outside of the U.S. and are currently
exploring the possibility of international
growth. Sanguina has the potential to make a
significant impact on improving the quality of
life in global populations.